REFLECT SCIENTIFIC, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that REFLECT SCIENTIFIC, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $1.08M | Mar 29, 2024 |
| FY2023 | Dec 31, 2022 | $2.04M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $2.81M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $2.79M | Mar 31, 2022 |
| FY2019 | Dec 31, 2019 | $1.61M | Mar 30, 2020 |
| FY2019 | Dec 31, 2018 | $1.55M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $1.07M | Apr 3, 2019 |
| FY2017 | Dec 31, 2016 | $1.19M | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | $1.04M | Mar 31, 2017 |
| FY2015 | Dec 31, 2014 | $1.53M | Mar 30, 2016 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $596.4K | Mar 29, 2024 |
| FY2023 | Dec 31, 2022 | $1.22M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $1.93M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $1.72M | Mar 31, 2022 |
| FY2019 | Dec 31, 2019 | $991.6K | Mar 30, 2020 |
| FY2019 | Dec 31, 2018 | $1.06M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $659.8K | Apr 3, 2019 |
| FY2017 | Dec 31, 2016 | $812.5K | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | $630.2K | Mar 31, 2017 |
| FY2015 | Dec 31, 2014 | $849.6K | Mar 30, 2016 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | ($459.0K) | Mar 29, 2024 |
| FY2023 | Dec 31, 2022 | $89.4K | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $939.1K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $660.1K | Mar 31, 2022 |
| FY2019 | Dec 31, 2019 | ($195.6K) | Mar 30, 2020 |
| FY2019 | Dec 31, 2018 | ($249.5K) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($402.2K) | Apr 3, 2019 |
| FY2017 | Dec 31, 2016 | ($216.2K) | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | $835.9K | Mar 31, 2017 |
| FY2015 | Sep 30, 2015 | $975.5K | Mar 30, 2016 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | ($467.3K) | Mar 29, 2024 |
| FY2023 | Dec 31, 2022 | $90.1K | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $827.8K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $651.0K | Mar 31, 2022 |
| FY2019 | Dec 31, 2019 | ($194.8K) | Mar 30, 2020 |
| FY2019 | Dec 31, 2018 | ($248.9K) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($402.2K) | Apr 3, 2019 |
| FY2017 | Dec 31, 2016 | ($251.6K) | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | ($460.0K) | Mar 31, 2017 |
| FY2015 | Dec 31, 2014 | ($718.6K) | Mar 30, 2016 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $29.5K | Mar 29, 2024 |
| FY2023 | Dec 31, 2022 | $73.4K | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $58.3K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $185.3K | Mar 31, 2022 |
| FY2019 | Dec 31, 2019 | $210.0K | Mar 30, 2020 |
| FY2019 | Dec 31, 2018 | $104.0K | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $46.7K | Apr 3, 2019 |
| FY2017 | Dec 31, 2016 | $70.8K | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | $72.9K | Mar 31, 2017 |
| FY2015 | Dec 31, 2014 | $22.1K | Mar 30, 2016 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | ($104.0K) | Mar 29, 2024 |
| FY2023 | Dec 31, 2022 | ($92.0K) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $831.4K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($25.2K) | Mar 31, 2022 |
| FY2014 | Dec 31, 2014 | $109.8K | Mar 31, 2015 |
| FY2014 | Dec 31, 2013 | ($55.6K) | Mar 31, 2015 |
| FY2013 | Dec 31, 2012 | ($91.1K) | Mar 31, 2014 |
| FY2012 | Dec 31, 2011 | $130.3K | Apr 1, 2013 |
| FY2011 | Dec 31, 2010 | $195.8K | Mar 30, 2012 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $2.67M | Mar 29, 2024 |
| FY2023 | Dec 31, 2022 | $2.45M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $2.48M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $1.68M | Mar 31, 2022 |
| FY2019 | Dec 31, 2018 | $1.08M | Mar 30, 2020 |
| FY2019 | Dec 31, 2017 | $592.7K | Mar 30, 2020 |
| FY2018 | Dec 31, 2016 | $579.8K | Apr 3, 2019 |
| FY2016 | Dec 31, 2015 | $706.4K | Mar 31, 2017 |
| FY2015 | Dec 31, 2014 | $843.4K | Mar 30, 2016 |
| FY2014 | Dec 31, 2013 | $857.7K | Mar 31, 2015 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $776.3K | Mar 29, 2024 |
| FY2023 | Dec 31, 2022 | $149.6K | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $299.2K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $463.3K | Mar 31, 2022 |
| FY2019 | Dec 31, 2018 | $525.8K | Mar 30, 2020 |
| FY2019 | Dec 31, 2017 | $74.9K | Mar 30, 2020 |
| FY2018 | Dec 31, 2016 | $124.4K | Apr 3, 2019 |
| FY2016 | Dec 31, 2015 | $151.7K | Mar 31, 2017 |
| FY2015 | Dec 31, 2014 | $1.41M | Mar 30, 2016 |
| FY2014 | Dec 31, 2013 | $1.36M | Mar 31, 2015 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $1.89M | Mar 29, 2024 |
| FY2023 | Dec 31, 2022 | $2.30M | Mar 29, 2024 |
| FY2023 | Dec 31, 2021 | $2.18M | Mar 29, 2024 |
| FY2022 | Dec 31, 2020 | $1.21M | Mar 31, 2023 |
| FY2021 | Dec 31, 2019 | $553.0K | Mar 31, 2022 |
| FY2019 | Dec 31, 2018 | $553.0K | Mar 30, 2020 |
| FY2019 | Dec 31, 2017 | $517.7K | Mar 30, 2020 |
| FY2018 | Dec 31, 2016 | $455.4K | Apr 3, 2019 |
| FY2017 | Dec 31, 2015 | $554.7K | Apr 2, 2018 |
| FY2016 | Dec 31, 2014 | ($566.5K) | Mar 31, 2017 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $60.0K | Mar 29, 2024 |
| FY2023 | Dec 31, 2022 | $60.0K | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $60.0K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $60.0K | Mar 31, 2022 |
| FY2019 | Dec 31, 2018 | $60.0K | Mar 30, 2020 |
| FY2019 | Dec 31, 2017 | $60.0K | Mar 30, 2020 |
| FY2018 | Dec 31, 2016 | $60.0K | Apr 3, 2019 |
| FY2016 | Dec 31, 2015 | $60.0K | Mar 31, 2017 |
| FY2015 | Dec 31, 2014 | $60.0K | Mar 30, 2016 |
| FY2014 | Dec 31, 2013 | $60.0K | Mar 31, 2015 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | ($19.27M) | Mar 29, 2024 |
| FY2023 | Dec 31, 2022 | ($18.81M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($18.90M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($19.84M) | Mar 31, 2022 |
| FY2019 | Dec 31, 2019 | ($20.50M) | Mar 30, 2020 |
| FY2019 | Dec 31, 2018 | ($20.50M) | Mar 30, 2020 |
| FY2019 | Dec 31, 2017 | ($20.30M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2016 | ($20.05M) | Apr 3, 2019 |
| FY2016 | Dec 31, 2015 | ($19.43M) | Mar 31, 2017 |
| FY2015 | Dec 31, 2014 | ($20.27M) | Mar 30, 2016 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $1.47M | Mar 31, 2022 |
| FY2021 | Dec 31, 2020 | $642.5K | Mar 31, 2022 |
| FY2021 | Dec 31, 2019 | $555.2K | Mar 31, 2022 |
| FY2019 | Dec 31, 2018 | $220.4K | Mar 30, 2020 |
| FY2019 | Dec 31, 2017 | $235.9K | Mar 30, 2020 |
| FY2018 | Dec 31, 2016 | $264.0K | Apr 3, 2019 |
| FY2017 | Dec 31, 2015 | $292.1K | Apr 2, 2018 |
| FY2016 | Dec 31, 2014 | $271.1K | Mar 31, 2017 |
| FY2015 | Dec 31, 2013 | $251.5K | Mar 30, 2016 |
| FY2014 | Dec 31, 2012 | $260.6K | Mar 31, 2015 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | 0 | Mar 29, 2024 |
| FY2023 | Dec 31, 2022 | 0 | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 31, 2022 |
| FY2018 | Dec 31, 2018 | 0 | Apr 3, 2019 |
| FY2018 | Dec 31, 2017 | 0 | Apr 3, 2019 |
| FY2015 | Dec 31, 2015 | 0 | Mar 30, 2016 |
| FY2015 | Dec 31, 2014 | 0 | Mar 30, 2016 |
| FY2014 | Dec 31, 2013 | 0 | Mar 31, 2015 |
| FY2013 | Dec 31, 2012 | 0 | Mar 31, 2014 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | 0 | Mar 29, 2024 |
| FY2023 | Dec 31, 2022 | 0 | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 31, 2022 |
| FY2018 | Dec 31, 2018 | 0 | Apr 3, 2019 |
| FY2018 | Dec 31, 2017 | 0 | Apr 3, 2019 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | 85.66M | Mar 29, 2024 |
| FY2023 | Dec 31, 2022 | 85.21M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | 84.99M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 84.74M | Mar 31, 2022 |
| FY2019 | Dec 31, 2019 | 84.74M | Mar 30, 2020 |
| FY2019 | Dec 31, 2018 | 79.11M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | 71.31M | Apr 3, 2019 |
| FY2017 | Dec 31, 2016 | 65.40M | Apr 2, 2018 |
| FY2017 | Dec 31, 2015 | 60.96M | Apr 2, 2018 |
| FY2016 | Dec 31, 2014 | 56.70M | Mar 31, 2017 |